Načítá se...
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease
BACKGROUND: Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β(2)-agonist (SABA) reliever use would...
Uloženo v:
| Vydáno v: | BMC Pulm Med |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4546184/ https://ncbi.nlm.nih.gov/pubmed/26293575 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-015-0077-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|